Mirati’s adagrasib scores encouraging results in KRAS-mutated lung cancer
Adagrasib is an investigational oral small-molecule inhibitor of KRAS G12C
Read More
Tag: KRAS mutation
Promising early results for new ovarian cancer drug combo
Drug combination could offer a new option for treatment-resistant advanced ovarian cancer
Read More
CRUK scientists develop drug that targets KRAS pathways
KRAS mutations are found in several hard-to-treat cancers
Read More
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
